| 中文名称 | 比马前列素 |
|---|---|
| 中文别名 | 比马前列素;(Z)-7-[(1R,2R,3R,5S)-3,5-二羟基-2-[(E,3S)-3-羟基-5-苯基戊-1-烯基]环戊基]-N-乙基庚-5-烯酰胺;比马前列腺素;贝美前列素;比马前列腺;比马前列素杂质;比马前列素及中间体;比马前列素 API;比马前列素原药;露泌根;贝美前列素(比马前列素);比马前列腺素/贝美前列素;贝美前列素杂质;比马前列腺素(对照品) |
| 英文名称 | Bimatoprost |
| 英文别名 | 17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE;BIMATOPROST;BIMATOPROST(TM);LUMIGAN;N-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDE;BIMATOPROST(LUMIGAN);17-phenyl-tri-norprostaglandin f2α-ethyl amide;(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide;(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide;Prostamide;C25H37NO4;17-phenyl trinor Prostaglandin F2α ethyl amide;AGN 192024;Bimatoprost (17-Phenyl-tri-norprostaglandin F2α-ethyl amide);BiMapnost;BiMatoprost HOUSE STANDARD;Bimatoprost API;cGMP Bimatoprost;Bimatoprost, >=99.5%;(15R)-BiMatoprost;(Z)-7-[(1S,2S,3R,5R)-3,5-Dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-e;(Z)-7-[(1S,2S,3R,5R)-3,5-Dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide;DURYSTA;(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide;(5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide;BIMATOPROST [VANDF];AS-35082;CHEMBL1200963;LS-181817;Latisse (TN);1ST159263;bimatoprostum;BIMATOPROST (MART.);Bimatoprost in bulk;SR-01000942224-1;5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-;QXS94885MZ;GANFORT COMPONENT BIMATOPROST;DB00905;Latisse;DTXSID30895042;BIMATOPROST [EMA EPAR];GTPL1958;EN300-21680860;BIMATOPROST [USAN];17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid;5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-;(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide;NCGC00181745-03;NCGC00181745-01;MFCD03411999;BDBM220120;NS00007742;5-HEPTENAMIDE, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYL-1-PENTENYL)CYCLOPENTYL)-N-ETHYL-, (1R-1(.ALPHA.(Z),2.BETA.(1E,3S*)3.ALPHA.,5.ALPHA.))-;BIMATOPROST [ORANGE BOOK];UNII-QXS94885MZ;Q2393348;155206-00-1;D02724;5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-;AGN-192024;5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-;(5Z)-BIMATOPROST;HY-B0191;MLS006010039;FD10460;US9271961, Bimatoprost;BIMATOPROST [MI];(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide;BIMATOPROST COMPONENT OF GANFORT;AKOS015995566;BIMATOPROST [JAN];SBI-0654129.0001;Lumigan (TN);B6165;EX-A1769;5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-;BIMATOPROST [INN];BIMATOPROST [WHO-DD];... |
| CAS No. | 155206-00-1 |
| 分子式 | C25H37NO4 |
| 分子量 | 415.57 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学